January 6, 2022 10:58 AM EST
R&D

Sang­amo's sick­le cell al­liance with Sanofi grinds to a halt as phar­ma gi­ant switch­es fo­cus to al­lo

Paul Schloesser

Associate Editor

Af­ter show­cas­ing clin­i­cal da­ta at #ASH21 for a sick­le cell dis­ease can­di­date, Sanofi has de­cid­ed to throw in the tow­el on its 8-year part­ner­ship with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times